文献速递肾移植

肾移植中抗体诱导治疗结局比较

Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.
PubMed 文献 · J Am Soc Nephrol · 2017-03-20

本研究将器官获取与移植网络数据与医疗保险理赔数据链接,采用基于15项临床和人口学特征匹配技术,比较阿仑单抗与兔抗胸腺细胞球蛋白(rATG)及巴利昔单抗与rATG诱导治疗的肾移植受者结局。结果显示,与rATG相比,阿仑单抗组死亡风险更高(HR 1.14,95%CI 1.03-1.26,P<0.01),巴利昔单抗组死亡风险亦更高(HR 1.08,95%CI 1.01-1.16,P=0.03);rATG与较低的不良结局风险相关。

要点

  • 阿仑单抗较rATG死亡风险更高(HR 1.14,95%CI 1.03-1.26,P<0.01)。
  • 巴利昔单抗较rATG死亡风险更高(HR 1.08,95%CI 1.01-1.16,P=0.03)。
  • rATG与较低的不良结局风险相关,包括死亡。

核心结论

  • 观察性证据表明,与阿仑单抗和巴利昔单抗相比,rATG与较低的不良结局风险相关,包括死亡。

研究设计与样本

  • 将器官获取与移植网络数据与医疗保险理赔数据链接,采用基于15项临床和人口学特征匹配技术,生成阿仑单抗-rATG 1:1配对5330对和巴利昔单抗-rATG 1:1配对9378对,使用配对Cox回归分析。

主要发现

  • 与rATG相比,阿仑单抗组死亡风险更高(HR 1.14,95%CI 1.03-1.26,P<0.01),死亡或同种异体移植物失败风险更高(HR 1.18,95%CI 1.09-1.28,P<0.001)。
  • 与rATG相比,巴利昔单抗组死亡风险更高(HR 1.08,95%CI 1.01-1.16,P=0.03),死亡或淋巴瘤风险更高(HR 1.12,95%CI 1.01-1.23,P=0.03),但亚组分析未证实这些差异。
  • 阿仑单抗组1年资源利用略低于rATG组,巴利昔单抗组与rATG组无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney transplant recipients often receive antibody induction. Previous studies of induction therapy were often limited by short follow-up and/or absence of information about complications. After linking Organ Procurement and Transplantation Network data with Medicare claims, we compared outcomes between three induction therapies for kidney recipients. Using novel matching techniques developed on the basis of 15 clinical and demographic characteristics, we generated 1:1 pairs of alemtuzumab-rabbit antithymocyte globulin (rATG) (5330 pairs) and basiliximab-rATG (9378 pairs) recipients. We used paired Cox regression to analyze the primary outcomes of death and death or allograft failure. Secondary outcomes included death or sepsis, death or lymphoma, death or melanoma, and healthcare resource utilization within 1 year. Compared with rATG recipients, alemtuzumab recipients had higher risk of death (hazard ratio [HR], 1.14; 95% confidence interval [95% CI], 1.03 to 1.26; P<0.01) and death or allograft failure (HR, 1.18; 95% CI, 1.09 to 1.28; P<0.001). Results for death as well as death or allograft failure were generally consistent among elderly and nonelderly subgroups and among pairs receiving oral prednisone. Compared with rATG recipients, basiliximab recipients had higher risk of death (HR, 1.08; 95% CI, 1.01 to 1.16; P=0.03) and death or lymphoma (HR, 1.12; 95% CI, 1.01 to 1.23; P=0.03), although these differences were not confirmed in subgroup analyses. One-year resource utilization was slightly lower among alemtuzumab recipients than among rATG recipients, but did not differ between basiliximab and rATG recipients. This observational evidence indicates that, compared with alemtuzumab and basiliximab, rATG associates with lower risk of adverse outcomes, including mortality.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Koyawala N, Silber JH, Rosenbaum PR, et al. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation. J Am Soc Nephrol. 2017. PMID: 28320767. doi:10.1681/ASN.2016070768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。